STARVE-PC: Biomarker-driven phase 2 study of ipilimumab plus nivolumab for AR-V7-expressing metastatic castration-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Boudadi, Karim
Suzman, Daniel L.
Luber, Brandon
Wang, Hao
Silberstein, John L.
Taylor, Maritza N.
Sullivan, Rana
Dowling, Donna
Harb, Rana
Dittamore, Ryan Vance
Meeker, Alan
Luo, Jun
Drake, Charles G.
Antonarakis, Emmanuel S.
机构：
[1] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[3] Johns Hopkins Univ Hosp, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA
[4] Johns Hopkins Med, Sidney Kimmel Comprehens Canc Ctr, Marriottsville, MD USA
[5] Johns Hopkins Univ, Baltimore, MD USA
[6] Epic Sci, San Diego, CA USA
[7] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[8] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS5089
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5089
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial
    Shenderov, Eugene
    Boudadi, Karim
    Fu, Wei
    Wang, Hao
    Sullivan, Rana
    Jordan, Alice
    Dowling, Donna
    Harb, Rana
    Schonhoft, Joseph
    Jendrisak, Adam
    Carducci, Michael A.
    Eisenberger, Mario A.
    Eshleman, James R.
    Luo, Jun
    Drake, Charles G.
    Pardoll, Drew M.
    Antonarakis, Emmanuel S.
    PROSTATE, 2021, 81 (06): : 326 - 338
  • [2] Phase 2 biomarker-driven study of ipilimumab plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC).
    Boudadi, Karim
    Suzman, Daniel L.
    Luber, Brandon
    Wang, Hao
    Silberstein, John
    Sullivan, Rana
    Dowling, Donna
    Harb, Rana
    Nirschl, Thomas
    Dittamore, Ryan Vance
    Carducci, Michael Anthony
    Eisenberger, Mario A.
    Haffner, Michael
    Meeker, Alan
    Eshleman, James R.
    Luo, Jun
    Drake, Charles G.
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).
    Sharma, Padmanee
    Pachynski, Russell Kent
    Narayan, Vivek
    Flechon, Aude
    Gravis, Gwenaelle
    Galsky, Matt D.
    Mahammedi, Hakim
    Patnaik, Akash
    Subudhi, Sumit Kumar
    Ciprotti, Marika
    Duan, Tao
    Saci, Abdel
    Hu, Sarah
    Han, G. Celine
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [4] Initial Results From a Phase 2 Study of Nivolumab Plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (04) : 8 - 10
  • [5] AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC).
    Antonarakis, Emmanuel S.
    Lu, Changxue
    Chen, Yan
    Luber, Brandon
    Wang, Hao
    Nakazawa, Mary
    De Marzo, Angelo M.
    Isaacs, William B.
    Nadal, Rosa
    Paller, Channing Judith
    Denmeade, Samuel R.
    Carducci, Michael Anthony
    Eisenberger, Mario A.
    Luo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [6] Phase II Study with metastatic castration-resistant Prostate Cancer (mCRPC) Patients
    Rexer, H.
    Graefen, M.
    UROLOGE, 2017, 56 (11): : 1468 - 1470
  • [7] A phase 2 study of cabozantinib and nivolumab in metastatic castration-resistant prostate cancer (CANOPY)
    Chen, Yu-Wei
    Liu, Lin
    Pu, Minya
    Pena, Samuel
    Qin, Qian
    Zhang, Tian
    Emamekhoo, Hamid
    Lang, Joshua Michael
    Patnaik, Akash
    McKkay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS239 - TPS239
  • [8] Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial
    Sharma, Padmanee
    Pachynski, Russell K.
    Narayan, Vivek
    Flechon, Aude
    Gravis, Gwenaelle
    Galsky, Matthew D.
    Mahammedi, Hakim
    Patnaik, Akash
    Subudhi, Sumit K.
    Ciprotti, Marika
    Simsek, Burcin
    Saci, Abdel
    Hu, Yanhua
    Han, G. Celine
    Fizazi, Karim
    CANCER CELL, 2020, 38 (04) : 489 - +
  • [9] Phase II study of cabazitaxel (CAB) plus enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC)
    Graff, Julie Nicole
    Cheng, Heather H.
    Vuky, Jacqueline
    Alumkal, Joshi J.
    Kreitner, Dustin
    Petreaca, Delia
    Grivas, Petros
    Schweizer, Michael Thomas
    Higano, Celestia S.
    Chen, Yiyi
    Yu, Evan Y.
    Beer, Tomasz M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [10] DETECTION OF AR-V7 TRANSCRIPTS IN WHOLE BLOOD RNA OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    Kwan, Edmond M.
    To, Sarah
    Fettke, Heidi
    Docanto, Maria
    Martelotto, Luciano
    Azad, Arun
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 50 - 50
12345